Debt-to-equity rose to 0.29 in 2026Q2 from 0.18 in 2026Q1, with total debt increasing by $1.0B sequentially, while goodwill of $8.3B represents 48% of total assets, suggesting acquisition-driven growth and potential impairment risk.
Xylem Inc. (XYL) balance sheet — 17-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|
| Total Current Assets | 4.39B | 4.64B | 4.09B | 3.88B | 3.01B | 3.16B | 3.52B | 2.45B | 2.09B | 2.07B | 1.84B | 2B | 2.06B | 2.01B | 1.87B | 1.64B | 1.34B | 1.09B |
| Cash & Short-Term Investments | 1.28B | 1.48B | 1.12B | 1.02B | 944M | 1.35B | 1.88B | 724M | 296M | 414M | 308M | 680M | 663M | 533M | 504M | 318M | 131M | 81M |
| Cash Only | 1.28B | 1.48B | 1.12B | 1.02B | 944M | 1.35B | 1.88B | 724M | 296M | 414M | 308M | 680M | 663M | 533M | 504M | 318M | 131M | 81M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.88B | 1.76B | 1.67B | 1.62B | 1.1B | 953M | 923M | 1.04B | 1.03B | 956M | 843M | 749M | 771M | 817M | 776M | 756M | 690M | 599M |
| Days Sales Outstanding | 72.32 | 71.06 | 71.11 | 80.15 | 72.44 | 66.96 | 69.09 | 72.04 | 72.27 | 74.13 | 81.6 | 74.84 | 71.86 | 77.72 | 74.71 | 72.56 | 78.65 | 76.74 |
| Inventory | 1.02B | 983M | 996M | 1.02B | 799M | 700M | 558M | 539M | 595M | 524M | 522M | 433M | 486M | 475M | 443M | 426M | 389M | 301M |
| Days Inventory Outstanding | 66.24 | 64.53 | 67.95 | 79.96 | 84.83 | 79.35 | 66.86 | 61.42 | 68.27 | 66.97 | 82.48 | 70.27 | 73.82 | 74.16 | 70.64 | 66.39 | 71.42 | 60.63 |
| Other Current Assets | 8M | 176M | 309M | 230M | 173M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41M | 41M | 45M | 47M | 54M |
| Total Non-Current Assets | 12.95B | 12.99B | 12.39B | 12.23B | 4.94B | 5.12B | 5.23B | 5.26B | 5.13B | 4.79B | 4.63B | 2.65B | 2.77B | 2.89B | 2.81B | 2.75B | 2.4B | 1.45B |
| Property, Plant & Equipment | 1.17B | 1.55B | 1.15B | 1.17B | 630M | 644M | 657M | 658M | 656M | 643M | 616M | 439M | 461M | 488M | 487M | 463M | 454M | 334M |
| Fixed Asset Turnover | 7.29x | 5.83x | 7.43x | 6.30x | 8.77x | 8.07x | 7.42x | 7.98x | 7.94x | 7.32x | 6.12x | 8.32x | 8.49x | 7.86x | 7.78x | 8.21x | 7.05x | 8.53x |
| Goodwill | 8.26B | 8.33B | 7.98B | 7.59B | 2.72B | 2.79B | 2.85B | 2.84B | 2.98B | 2.77B | 2.63B | 1.58B | 1.64B | 1.72B | 1.65B | 1.61B | 1.44B | 970M |
| Intangible Assets | 2.15B | 2.27B | 2.38B | 2.53B | 930M | 1.02B | 1.09B | 1.17B | 1.23B | 1.17B | 1.2B | 435M | 431M | 488M | 484M | 505M | 416M | 91M |
| Long-Term Investments | 8M | 0 | 50M | 9M | 79M | 8M | 0 | 4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.37B | 698M | 834M | 934M | 582M | 656M | 623M | 585M | 264M | 210M | 186M | 194M | 203M | 193M | 187M | 173M | 92M | 52M |
| Total Assets | 17.34B | 17.63B | 16.49B | 16.11B | 7.95B | 8.28B | 8.75B | 7.71B | 7.22B | 6.86B | 6.47B | 4.66B | 4.83B | 4.9B | 4.68B | 4.39B | 3.73B | 2.54B |
| Asset Turnover | 0.53x | 0.51x | 0.52x | 0.46x | 0.69x | 0.63x | 0.56x | 0.68x | 0.72x | 0.69x | 0.58x | 0.78x | 0.81x | 0.78x | 0.81x | 0.87x | 0.86x | 1.12x |
| Asset Growth % | 17.97% | 6.92% | 2.36% | 102.62% | -3.91% | -5.42% | 13.49% | 6.76% | 5.28% | 5.96% | 39.02% | -3.64% | -1.29% | 4.64% | 6.51% | 17.62% | 47.34% | - |
| Total Current Liabilities | 2.72B | 2.86B | 2.34B | 2.21B | 1.59B | 1.39B | 1.96B | 1.5B | 1.39B | 1.1B | 1.24B | 823M | 903M | 853M | 781M | 817M | 649M | 571M |
| Accounts Payable | 1.01B | 1.01B | 1.01B | 968M | 723M | 639M | 569M | 597M | 586M | 549M | 457M | 338M | 338M | 332M | 332M | 322M | 297M | 238M |
| Days Payables Outstanding | 65.22 | 66.5 | 68.63 | 76.03 | 76.76 | 72.43 | 68.18 | 68.03 | 67.24 | 70.16 | 72.21 | 54.86 | 51.34 | 51.83 | 52.94 | 50.18 | 54.53 | 47.94 |
| Short-Term Debt | 531M | 534M | 38M | 16M | 69M | 69M | 663M | 337M | 257M | 0 | 260M | 78M | 89M | 42M | 6M | 5M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 309M | 443M | 430M | 403M | 285M | 273M | 258M | 156M | 194M | 203M | 182M | 156M | 186M | 144M | 201M | 219M | 224M | 162M |
| Current Ratio | 1.61x | 1.63x | 1.75x | 1.76x | 1.89x | 2.27x | 1.80x | 1.63x | 1.51x | 1.88x | 1.49x | 2.44x | 2.29x | 2.36x | 2.40x | 2.01x | 2.06x | 1.91x |
| Quick Ratio | 1.24x | 1.28x | 1.33x | 1.30x | 1.39x | 1.77x | 1.52x | 1.27x | 1.08x | 1.41x | 1.06x | 1.91x | 1.75x | 1.80x | 1.83x | 1.49x | 1.46x | 1.38x |
| Cash Conversion Cycle | 73.34 | 69.09 | 70.42 | 84.07 | 80.51 | 73.87 | 67.77 | 65.43 | 73.3 | 70.94 | 91.87 | 90.26 | 94.34 | 100.04 | 92.41 | 88.77 | 95.55 | 89.43 |
| Total Non-Current Liabilities | 3.95B | 3.03B | 3.27B | 3.73B | 2.86B | 3.66B | 3.82B | 3.24B | 3.05B | 3.24B | 3.03B | 1.75B | 1.83B | 1.8B | 1.82B | 1.75B | 367M | 277M |
| Long-Term Debt | 2.4B | 1.41B | 1.98B | 2.27B | 1.88B | 2.44B | 2.48B | 2.04B | 2.05B | 2.2B | 2.11B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | 4M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 1.78B | 405M | 497M | 557M | 222M | 287M | 242M | 310M | 303M | 252M | 352M | 118M | 158M | 191M | 173M | 165M | 99M | 60M |
| Other Non-Current Liabilities | 1.11B | 1.22B | 800M | 906M | 757M | 932M | 1.09B | 892M | 697M | 789M | 569M | 436M | 472M | 412M | 452M | 383M | 264M | 217M |
| Total Liabilities | 6.92B | 5.88B | 5.62B | 5.94B | 4.45B | 5.05B | 5.77B | 4.74B | 4.44B | 4.34B | 4.27B | 2.57B | 2.74B | 2.65B | 2.6B | 2.57B | 1.02B | 848M |
| Total Debt | 3.06B | 2.06B | 2.13B | 2.39B | 1.95B | 2.51B | 3.15B | 2.38B | 2.31B | 2.2B | 2.37B | 1.27B | 1.28B | 1.24B | 1.21B | 1.21B | 4M | 0 |
| Net Debt | 1.78B | 584M | 1B | 1.37B | 1B | 1.16B | 1.27B | 1.65B | 2.01B | 1.79B | 2.06B | 594M | 621M | 708M | 701M | 888M | -127M | -81M |
| Debt / Equity | 0.29x | 0.18x | 0.20x | 0.23x | 0.56x | 0.78x | 1.06x | 0.80x | 0.83x | 0.87x | 1.07x | 0.61x | 0.60x | 0.55x | 0.58x | 0.66x | 0.00x | - |
| Debt / EBITDA | 1.62x | 1.15x | 1.35x | 2.20x | 2.27x | 3.02x | 5.09x | 3.20x | 2.52x | 2.80x | 4.25x | 2.19x | 2.12x | 2.42x | 1.92x | 2.27x | 0.01x | - |
| Net Debt / EBITDA | 0.94x | 0.32x | 0.64x | 1.26x | 1.17x | 1.40x | 2.06x | 2.22x | 2.20x | 2.27x | 3.70x | 1.02x | 1.03x | 1.38x | 1.12x | 1.67x | -0.26x | -0.23x |
| Interest Coverage | 56.35x | 41.72x | 25.70x | 13.96x | 9.80x | 7.72x | 4.70x | 7.21x | 8.38x | 7.07x | 6.94x | 8.27x | 9.06x | 8.24x | 8.05x | 23.53x | - | - |
| Total Equity | 10.42B | 11.75B | 10.88B | 10.18B | 3.5B | 3.23B | 2.98B | 2.97B | 2.78B | 2.52B | 2.21B | 2.08B | 2.13B | 2.24B | 2.07B | 1.83B | 2.72B | 1.69B |
| Equity Growth % | 9.7% | 7.97% | 6.94% | 190.49% | 8.59% | 8.4% | 0.3% | 6.65% | 10.44% | 14.14% | 5.9% | -2.02% | -5.09% | 8.05% | 13.52% | -32.81% | 61.17% | - |
| Book Value per Share | 44.06 | 48.15 | 44.69 | 46.64 | 19.36 | 17.77 | 16.43 | 16.37 | 15.36 | 13.92 | 12.26 | 11.47 | 11.55 | 12.05 | 11.14 | 9.86 | 14.73 | 9.14 |
| Total Shareholders' Equity | 10.42B | 11.48B | 10.64B | 10.17B | 3.49B | 3.22B | 2.97B | 2.96B | 2.77B | 2.5B | 2.19B | 2.08B | 2.13B | 2.24B | 2.07B | 1.83B | 2.72B | 1.69B |
| Common Stock | 3M | 3M | 3M | 3M | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2.36B | 1.27B |
| Retained Earnings | 3.96B | 3.71B | 3.14B | 2.6B | 2.29B | 2.15B | 1.93B | 1.87B | 1.64B | 1.23B | 1.03B | 885M | 648M | 405M | 264M | 40M | 0 | 0 |
| Treasury Stock | -2.02B | -768M | -753M | -733M | -708M | -656M | -588M | -527M | -487M | -428M | -403M | -399M | -220M | -86M | -13M | 0 | 0 | 0 |
| Accumulated OCI | -302M | -220M | -435M | -269M | -226M | -371M | -413M | -375M | -336M | -210M | -318M | -238M | -99M | 167M | 115M | 122M | 358M | 415M |
| Minority Interest | 3M | 269M | 240M | 10M | 9M | 8M | 8M | 10M | 14M | 16M | 17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying XYL stock.
As of 2025, Xylem Inc. (XYL) had total assets of $17.63B including $4.64B in current assets.
Xylem Inc. (XYL) carries total debt of $2.06B, offset by $1.48B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Xylem Inc. (XYL) has total shareholders' equity (book value) of $11.48B ($48.15 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Xylem Inc. (XYL) reported a current ratio of 1.63x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Integration and international softness
Metrics are mathematically derived from official filings.
Balance Sheet Expansion with Rising Leverage
Total assets grew to $17.3B in 2026Q2 from $15.9B in 2024Q1, per reported figures, while debt-to-equity rose to 0.29 from 0.23, indicating a shift toward leverage.
The balance sheet has expanded steadily, driven largely by retained earnings growth from $2.7B to $4.0B over the period. However, the recent jump in total debt to $3.1B in 2026Q2 from $2.1B in the prior quarter suggests a strategic increase in leverage, possibly to fund capital returns or acquisitions. This trend warrants monitoring as it may signal a departure from the historically conservative capital structure.
Leverage Inflection Points to Strategic Shift
Debt-to-equity rose to 0.29 in 2026Q2 from 0.18 in 2026Q1, as reported in financial statements, while total debt increased by $1.0B sequentially, suggesting a deliberate leverage increase.
The sharp increase in debt in 2026Q2 appears to be a strategic move, possibly to finance share repurchases or acquisitions, given the concurrent rise in retained earnings. Despite the increase, leverage remains moderate compared to peers like Pentair (D/E 0.46), indicating ample headroom. Investors should monitor whether this leverage is a one-time event or a new trend, as it could impact future cash flow durability.
Asset Mix Reflects Acquisition-Driven Growth
Goodwill rose to $8.3B in 2026Q2 from $7.5B in 2024Q1, per SEC filings, now representing 48% of total assets, while PPE remained stable at $1.2B, indicating an asset-light model.
The significant goodwill balance, largely from the Evoqua and Sensus acquisitions, underscores the company's strategy of growth through M&A rather than organic capital expenditure. The stable PPE suggests a mature asset base with maintenance-focused spending. However, the high goodwill concentration poses an impairment risk if integration fails to deliver expected synergies, which could pressure future earnings.
Retained Earnings Drive Equity Quality
Equity grew to $10.4B in 2026Q2 from $10.2B in 2024Q1, as reported, with retained earnings increasing by $1.3B, indicating strong internal capital generation.
The growth in equity is primarily attributable to retained earnings, which rose from $2.7B to $4.0B over the period, reflecting consistent profitability. The absence of significant stock-based compensation, as noted in prior analysis, suggests reported earnings are not diluted by non-cash charges. This high-quality equity base supports the company's ability to fund future investments and return capital to shareholders.
Liquidity Buffer Remains Adequate
Current ratio improved to 1.61 in 2026Q2 from 1.46 in 2026Q1, per reported figures, while cash rose to $1.3B, providing a cushion against short-term obligations.
The current ratio, though slightly below the 2025Q3 peak of 1.96, remains above 1.5, indicating sufficient short-term liquidity. Cash increased to $1.3B, up from $808M in the prior quarter, likely due to debt issuance. This buffer appears adequate to cover operational needs and potential working capital swings, though the reliance on debt for liquidity is a point to monitor.
Goodwill Concentration Masks Asset Quality
Goodwill of $8.3B represents 48% of total assets as of 2026Q2, per financial statements, a level that could distort return-on-asset metrics and signal impairment risk.
The substantial goodwill balance, a result of aggressive acquisition strategy, may overstate the company's asset base and understate its true economic returns. If the anticipated synergies from Evoqua fail to materialize, an impairment charge could significantly reduce equity and earnings. Investors should scrutinize the performance of acquired segments, particularly MCS, to assess the sustainability of the current asset valuation.